ImmuCell Q2 2026 net income $1.8M, revenue up 11.5% to $7.2M

IMMUCELL CORP /DE/

Net income $1.8M ($0.20 diluted EPS) vs $0.5M ($0.06) in Q2 2025; adjusted EBITDA $2.7M vs $1.4M.
Product sales $7.2M, +11.5% YoY; gross margin fell to 33.9% from 43.7% on lower volumes and quality scrap.
Received $2M legal settlement from former Re-Tain contract manufacturer, boosting net income.
Cash rose to $8.9M from $3.8M at year-end; working capital $16.6M, equity $31.4M.
Plans ~$3.5M freeze-drying capacity (H1 2027) and ~$4.5M liquid processing expansion; aims to triple capacity in 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.